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Abstract 
α1-antitrypsin deficiency is characterised by the misfolding and intracellular 
polymerisation of mutant α1-antitrypsin within the endoplasmic reticulum of 
hepatocytes.  The retention of mutant protein causes hepatic damage and 
cirrhosis whilst the lack of an important circulating protease inhibitor 
predisposes the individuals with severe α1-antitrypsin deficiency to early onset 
emphysema.  Our work over the past 25 years has led to new paradigms for 
the liver and lung disease associated with α1-antitrypsin deficiency.  We 
review here the molecular pathology of the cirrhosis and emphysema 
associated with α1-antitrypsin deficiency and show how an understanding of 
this condition provided the paradigm for a wider group of disorders that we 
have termed the serpinopathies.  The detailed understanding of the 
pathobiology of α1-antitrypsin deficiency has identified important disease 
mechanisms to target.  As a result, several novel parallel and complementary 
therapeutic approaches are in development with some now in clinical trials.  
We provide an overview of these new therapies for the liver and lung disease 
associated with α1-antitrypsin deficiency. 
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Introduction 
 
We have described a group of protein conformational diseases that we have 
termed the serpinopathies [1].  They are characterised by the misfolding and 
intracellular polymerisation of members of the serine protease inhibitor or 
serpin superfamily.  The best characterised of the serpinopathies is α1-
antitrypsin deficiency [2].  This is one of the most common genetic disorders 
with the severe Z deficiency allele (Glu342Lys) being present in 1:25 of the 
North European Caucasian population of whom 1:2000 are homozygotes.  
The Z mutation causes the retention of protein within hepatocytes in 
association with neonatal hepatitis, cirrhosis and hepatocellular carcinoma [3-
5]. There is no specific treatment for the liver disease associated with α1-
antitrypsin deficiency which accounts for 3.5% and 1.1% of paediatric and 
adult liver transplants in the UK respectively.   
The lack of α1-antitrypsin, an important protease inhibitor, predisposes the Z 
homozygote to early onset panlobular basal emphysema [6]. α1-antitrypsin 
deficiency is the only known genetic cause of emphysema and is found in 1-
2% of all individuals with chronic obstructive pulmonary disease (COPD);  
COPD will be the third commonest cause of death worldwide by 2020.  The 
only treatment directly targeting the underlying pathobiology of the lung 
disease is α1-antitrypsin augmentation therapy which costs approximately 
$100,000/patient/year. Alpha1-antitrypsin deficiency accounts for 3.2% of 
adult lung transplants and 10% of all lung transplants for emphysema in the 
UK.  Our work over the past 25 years has led to a new paradigm for α1-
antitrypsin deficiency.  Here we review the molecular basis of α1-antitrypsin 
deficiency and provide an update of the therapeutic strategies that are being 
developed. 
 
Polymerisation: the central feature of α1-antitrypsin deficiency 
 
Alpha1-antitrypsin is the archetypal member of the serpin superfamily. The 
wild-type M protein is a 394 residue, 52kDa glycoprotein that is synthesised 
by hepatocytes, but is also produced by lung and gut epithelial cells, 
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neutrophils and alveolar macrophages.  Alpha1-antitrypsin is the major 
circulating antiprotease but its key function is regulation of the proteolytic 
effects of neutrophil elastase within the lung.  We showed that the severe Z 
deficiency mutant of α1-antitrypsin is retained within the endoplasmic 
reticulum (ER) of hepatocytes as ordered polymers that become sequestered 
in Periodic Acid Schiff-positive, diastase-resistant inclusions [2, 7].  We have 
used biophysical and crystallographic techniques to dissect the pathway of α1-
antitrypsin polymerisation [8-12].  Our work suggests that the Z mutation 
perturbs its local environment (breach region, Fig. 1A) to favour population of 
an unstable intermediate that we termed M* [8] in which β-sheet A opens [2, 
8] and the upper part of helix F unwinds [9, 13, 14].  The patent β-sheet A can 
then accept insertion of the reactive site loop motif.  Sequential insertion of 
the loop of one α1-antitrypsin molecule into β-sheet A of a neighbour to form 
first a loop-sheet dimer, and then longer species linking more molecules, is 
the simplest model to explain the formation of elongated polymers [2, 8, 15] 
(Fig. 1B(i)).  Indeed, polymerisation is blocked by peptides that mimic the 
reactive loop sequence and so compete for binding to the insertion site in β-
sheet A [2, 16].  We subsequently showed that the same process explains the 
profound plasma deficiency and hepatic inclusions of 3 other mutants of α1-
antitrypsin: Siiyama (Ser53Phe) [17], Mmalton (∆Phe52) [18] and King’s 
(His334Asp) [7].  Polymerisation also underlies the deficiency of the mild S 
(Glu264Val), I (Arg39Cys), Queen's (Lys154Asn) and Baghdad (Ala336Pro) 
alleles of α1-antitrypsin [12, 14, 19, 20] but the rate of polymer formation is 
much slower in keeping with the absence of liver disease and only mild 
plasma deficiency.  In many cases the reduction in the thermal stability of the 
native fold of α1-antitrypsin caused by mutations directly correlates with the 
polymerogenic tendency [11].  This implies that the mutants’ conformational 
behaviour is qualitatively similar to that of wild-type α1-antitrypsin, but that 
destabilised states become accessible at lower temperatures.  However in 
some cases, disease mutations appear to cause polymerisation more by 
altering the balance of conformational behaviour (kinetic destabilisation) 
between native and intermediate states to favour population of the latter [21].  
Importantly one such exception is the Z variant, that appears to cause a 
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relatively mild thermal destabilisation but is highly polymerogenic [11, 12, 16].  
Understanding the polymerogenic behaviour of the most clinically-significant 
variant is important as it has relevance for the readouts that may be used in 
screening for therapeutic agents [16, 22].  Conversely, understanding the 
behaviour of rarer or milder variants in addition opens the way to precision 
medicine approaches, analogous to recent advances in cystic fibrosis [23, 24].  
 
Controversies on the structure of the pathological polymer 
 
Our original description of polymers of Z α1-antitrypsin envisaged a linkage 
between the reactive centre loop and β-sheet A [2] (Fig. 1B(i)).  Clinically, Z 
α1-antitrypsin inclusions within hepatocytes are increased by pyrexia and we 
assumed that polymers generated in vitro by heating purified Z α1-antitrypsin 
would be identical to those formed in vivo.  We further assumed that polymers 
generated in vitro would be identical whether they were formed by heating 
purified Z α1-antitrypsin or incubation with denaturants (urea or guanidine) [8].  
However we now know the latter assumption was incorrect, and the former 
assumption is also a matter of debate [22].  An alternative linkage was 
suggested by the crystal structures of a dimer of antithrombin in which the 
molecules were linked by a β-hairpin of the reactive centre loop and strand 5A 
[25] (Fig. 1B (ii)).  The biophysical characteristics of polymers of α1-antitrypsin 
formed by refolding from guanidine gave support to the β-hairpin linkage [26].  
The cause of the disparate findings became clear with our development of the 
2C1 monoclonal antibody that recognises polymers from the livers of 
individuals with α1-antitrypsin deficiency [7].  This antibody binds polymers 
formed by heating monomeric α1-antitrypsin, but not those formed by refolding 
from guanidine and urea [15].  Our NMR studies followed the polymerisation 
of Queen’s (Lys154Asn) α1-antitrypsin under physiological conditions or in 
urea. Intermediate (M*) formation under physiological conditions was 
associated with highly native-like behaviour with changes in a few key motifs 
[14].  Global changes were observed in urea consistent with more widespread 
unfolding, in keeping with data from hydrogen-deuterium exchange [27]. 
Consequently different polymeric linkages can be accessed by different 
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denaturing conditions. The application of heat to monomeric α1-antitrypsin 
recapitulated the 2C1 neo-epitope of polymers associated with disease [15]. 
This neo-epitope is also observed in self-terminating trimers of Z α1-
antitrypsin artificially constrained by disulphide bonds and purified from the 
cytosol of a yeast expression system [28].  This species was crystallised and 
the structure determined to 3.9 Å resolution.  The structure revealed yet 
another stable linkage mechanism, this time via complementary 
intermolecular insertion of the C-terminal triple-strand motif (Fig. 1B (iii)).  This 
mechanism again requires a substantially unfolded intermediate state, 
associated with intramolecular insertion of the reactive site loop.  Recent work 
using small-angle X-ray scattering (SAXS) suggested that the trimer, tetramer, 
and pentamer of Z α1-antitrypsin all form ring-like structures in keeping with C-
terminal domain-swap mechanism of polymerisation [29].  However ring 
structures are only rarely seen in inclusions from the livers of individuals with 
Z α1-antitrypsin deficiency ([2] and Fig. 2).  
 
Intracellular processing of α1-antitrypsin polymers 
Approximately 70% of Z α1-antitrypsin is degraded within hepatocytes by ER 
associated degradation (ERAD) [30].  Fifteen percent folds effectively and is 
secreted, while the remainder self-associates to form polymers.  These are in 
part degraded by autophagy, but a proportion persist in intractable inclusions 
[30, 31].  Misfolded proteins within the ER lumen usually trigger adaptive 
measures termed the unfolded protein response (UPR).  Indeed, terminally 
misfolded truncated variants of α1-antitrypsin (e.g., α1-antitrypsin Null-
HongKong and Saar) constitutively activate the UPR [32, 33].  Surprisingly, 
the accumulation of Z α1-antitrypsin polymers within the ER is not associated 
with UPR activation in cell lines that recapitulate hepatocyte phenotypes or in 
transgenic mice, possibly because polymers are structurally ordered (Fig. 3).  
Instead Z α1-antitrypsin expression activates NFκB by a calcium-mediated 
pathway that is independent of the UPR [32-35].  We have termed this the 
'ordered protein response' [35] and others have shown that it results in the 
release of IL-6 and IL-8 [34].  These cytokines are well-recognised mediators 
of both acute and chronic inflammatory responses and so may play 
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pathogenic roles in both the liver and lung disease associated with α1-
antitrypsin deficiency.  Moreover, cells expressing Z α1-antitrypsin display a 
more marked UPR when stressed with a 'second hit' [33, 34].  We have 
proposed that this results from α1-antitrypsin polymers increasing the viscosity 
within the ER thereby reducing the mobility of chaperones and hence their 
ability to neutralise the effect of a second insult [33]. 
 
Alpha1-antitrypsin polymers, inflammation and emphysema 
 
The study of the rare null mutations of α1-antitrypsin provides compelling 
evidence that the lack of circulating α1-antitrypsin plays a central role in the 
development of emphysema [36]. Consistent with this, α1-antitrypsin variants 
that fold more successfully and are less polymerogenic than the Z variant 
have higher circulating levels of α1-antitrypsin and appear to be associated 
with far lower risks of lung disease. Indeed such variants are typically 
described in association with lung disease in compound heterozygous states 
together with one Z allele (e.g. SZ individuals [37, 38]).  The recognition that 
polymers were present within hepatocytes raised the question that they may 
also be present within the lung.  Polymers are detectable in bronchoalveolar 
lavage from Z α1-antitrypsin homozygotes [39].  They have even been found 
after a Z α1-antitrypsin individual had undergone a liver transplant i.e. the 
subject received a M α1-antitrypsin liver [40].  This elegant clinical experiment 
demonstrated that pulmonary polymers may arise from local production.  
However we have been unable to detect polymers in our studies assessing 
primary bronchial epithelial cells [41].  Polymers of α1-antitrypsin form within 
the lung as a result of local inflammation and exposure to cigarette smoke [39, 
40, 42, 43].  They are pro-inflammatory for human neutrophils in vitro [40, 44] 
and in murine lungs in vivo [42].  Moreover cigarette smoke induces both 
intrapulmonary polymer formation and neutrophil influx in transgenic mice that 
express Z, but not M α1-antitrypsin [43].  Polymers have also been identified in 
the skin of an individual with α1-antitrypsin deficiency and panniculitis and in a 
renal biopsy of an individual with α1-antitrypsin deficiency and vasculitis.  We 
have recently shown that circulating polymers of α1-antitrypsin are present in 
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all individuals with ZZ α1-antitrypsin deficiency (mean 36.3+/-SD33.3µg/mL; 
n=517) and that the level is associated with COPD (OR 3.6, 95% CI 1.4–9.1) 
[45].  These observations provide a new paradigm for the pathogenesis of the 
emphysema associated with α1-antitrypsin deficiency - a combination of loss 
of anti-protease function combined with pro-inflammatory intrapulmonary 
polymers [44].  However it is still unknown whether the pro-inflammatory 
properties of polymers play an important role in the pathogenesis of the 
emphysema associated with α1-antitrypsin deficiency or whether the majority 
of the pathology is driven by the deficiency in the antiproteinase screen (Fig. 
3).  Also, the balance of polymers derived from plasma Z α1-antitrypsin and 
from local production within the lung is unresolved.  
 
Polymers and the serpinopathies 
 
Alpha1-antitrypsin is a member of a family of serine proteinase inhibitors 
termed the serpins.  We and others reported the same process of 
polymerisation in different members of the family in association with a range 
of diseases: polymerisation of mutants of C1-inhibitor are associated with 
plasma deficiency and angio-oedema; polymerisation of mutants of 
antithrombin cause plasma deficiency in association with thrombosis and the 
polymerisation of mutants of α1-antichymotrypsin cause plasma deficiency 
that in some studies is associated with emphysema.  A mutation in heparin 
co-factor II (Glu428Lys) that is homologous to the Z allele of α1-antitrypsin is 
associated with plasma deficiency but as yet this has not been shown to 
cause disease [1, 46].   
The process of disease-related polymerisation is most striking for mutations 
in the neurone-specific serpin neuroserpin.  We showed that mutations in 
neuroserpin result in the formation of polymers that are retained as neuronal 
inclusions in the cerebral cortex [47].  These inclusions result in an autosomal 
dominant dementia that we called familial encephalopathy with neuroserpin 
inclusion bodies or FENIB [47, 48].  Six mutations have now been described 
that underlie FENIB [48-50].  We have assessed a range of mutants of 
different severity in purified recombinant protein, cell, fly, worm and mouse 
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models of disease [48, 51-57].  The data show a direct relationship between 
the severity of the mutation, the rate of polymer formation and the severity of 
the associated dementia.  In view of the common molecular mechanism 
underlying these disorders we grouped them together as a new class of 
disease-the serpinopathies [1].  The serpinopathies can cause disease by (i) a 
toxic gain of function from the accumulated protein, as in α1-antitrypsin 
deficiency [2] and the dementia FENIB [47] and (ii) from the lack of an 
important circulating inhibitor as occurs in deficiency of α1-antitrypsin 
(emphysema), antithrombin (thrombosis), C1-inhibitor (angio-oedema) and α1-
antichymotrypsin (emphysema) [58, 59].  Moreover what is learned from α1-
antitrypsin and neuroserpin is likely to be applicable to an entire family of 
disease. 
 
Towards an effective therapy for α1-antitrypsin deficiency.   
 
Behavioural approaches 
The most effective current therapies for α1-antitrypsin deficiency are 
preventive.  It is essential that individuals with severe α1-antitrypsin deficiency 
abstain from smoking, and ideally avoid passive exposures including dusty 
occupations [60].  This will help to preserve lung function.  We also strongly 
advise against excessive consumption of alcohol §and avoiding excessive 
weight gain.  Both alcohol consumption and high body-mass index (via fatty 
liver) can cause liver damage in addition to that caused by α1-antitrypsin 
deficiency. 
 
Treatment for lung disease associated with α1-antitrypsin deficiency 
(i) Replacement therapy 
The mainstay of treatment for severe α1-antitrypsin deficiency in many 
countries is the correction of the plasma deficiency with intravenous 
augmentation of pooled plasma purified α1-antitrypsin [61].  Augmentation 
therapy is associated with a reduction in the frequency of respiratory tract 
infections and a decline in sputum markers of inflammation.  Two randomised 
clinical trials have been undertaken but neither has shown that augmentation 
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therapy reduces the rate of decline in lung function [62, 63].  We have 
postulated that this is because the lung disease associated with α1-antitrypsin 
deficiency is caused by more than the deficiency of an important antiprotease; 
the pro-inflammatory intrapulmonary polymers may negate the antiprotease 
effect of intravenous replacement therapy [44, 64].  Moreover, the relevance 
of decline in forced expiratory volume in 1 s (FEV1) as an endpoint in 
respiratory disease is increasingly debated given recent data highlighting a 
developmental cause for reduced lung function [65].  The RAPID investigators 
have recently reported a 24 month study in which 93 individuals were 
randomised to active therapy and 87 to received placebo [66].  The annual 
rate of lung density loss at total lung capacity (TLC) and functional residual 
capacity (FRC) combined did not differ between groups.  However, the annual 
rate of lung density loss at TLC alone was significantly less in patients in the 
group that received augmentation therapy (difference 0·74 g/L per year [95% 
confidence interval 0·06–1·42], p=0·03) but there was no difference at FRC 
alone (difference 0·48 g/L per year [–0·22 to 1·18], p=0·18).  It is unclear how 
this difference at TLC translates to clinical benefit or if a subgroup can be 
identified that particularly benefit from augmentation therapy.  Nevertheless 
the study has been interpreted positively by the European Medicines Agency 
who have recently granted a licence for augmentation therapy in individuals 
with α1-antitrypsin deficiency.  The UK National Institute for Clinical 
Excellence (NICE) will now need to rule whether the difference in lung density 
represents value for money in a managed health care system.   
Augmentation therapy is not given with the intention of affecting the liver 
disease associated with α1-antitrypsin deficiency which appears to be 
predominantly driven by misfolding and polymerisation rather than loss-of-
function.  Theoretically there may be benefit if the excessive synthesis, 
misfolding and polymerisation of Z α1-antitrypsin is driven by an, as yet 
undefined, negative feedback loop driven by low levels of extracellular protein.  
Moreover, anti-apoptotic and anti-inflammatory effects of extracellular α1-
antitrypsin have been invoked to explain beneficial effects of α1-antitrypsin in 
a mouse model of acute liver failure [67].  Nevertheless, to date no data have 
indicated any signal of benefit with this treatment in liver disease.   
  
 11
 
(ii) Alternative approaches to deliver α1-antitrypsin replacement therapy 
There are several alternative approaches to restore circulating levels of α1-
antitrypsin and so protect individuals against the development of emphysema.    
These include the production of recombinant α1-antitrypsin for replacement 
therapy and the delivery of α1-antitrypsin by an inhaled route that should 
significantly reduce the amount that is required to counter the effect of 
neutrophil elastase.  A third approach is gene-based therapy using non-viral 
gene transfer, gamma-retrovirus, recombinant adenovirus (rAd), and 
recombinant adeno-associated virus (rAAV) vectors.  One rAAV vector has 
been assessed in a phase II clinical trial, showing promise but only achieving 
3-5% of the target range of α1-antitrypsin [68].  
 
(iii) Retinoic acid 
Retinoic acid abrogates elastase-induced emphysema in rats [69] and so 
was evaluated in man [70].  133 and 129 individuals with severe α1-antitrypsin 
deficiency were randomised to placebo or 5 mg/day palovarotene (an oral γ-
selective retinoid agonist) respectively for 1 year (the REPAIR study: Retinoid 
treatment of Emphysema in Patients on the α1-antitrypsin International 
Registry).  Palovarotene was generally well tolerated but there was no 
significant benefit on lung density in individuals with moderate-to-severe 
emphysema. 
 
(iv) Symptomatic therapy, transplantation, lung volume reduction surgery and 
endobronchial valves 
In the absence of specific therapy, individuals with α1-antitrypsin deficiency 
lung disease should be considered for therapies used in α1-antitrypsin replete 
COPD.  These include pulmonary rehabilitation, vaccination and the use of 
inhaled pharmacotherapies including (alone or in combination) inhaled 
corticosteroids, long-acting beta-agonists and long-acting anti-cholinergics 
currently based on multi-component patient assessment of symptoms, lung 
function impairment and exacerbation frequency.  It should be noted, 
however, that α1-antitrypsin deficiency has often been an exclusion criteria in 
clinical trials of these approaches in ‘usual’ COPD.   
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The most effective therapy for individuals with severe airflow obstruction is 
single lung transplantation.  However given the limited availability of donor 
organs, lung volume reduction surgery (LVRS) must be considered in these 
individuals possibly as definitive therapy, but more likely as a bridge to 
transplantation.  However the benefits derived from LVRS in individuals with 
α1-antitrypsin deficiency is inferior to that of individuals who have 'usual' 
COPD.  Further work is necessary to determine whether there is a subgroup 
of individuals with α1-antitrypsin deficiency who derive more long-lasting 
improvement from this intervention [71]. 
Endobronchial lung volume reduction (ELVR) performed by one-way valves 
inserted via a flexible bronchoscope can result in a moderate but significant 
improvement in lung function and exercise tolerance, eliminating the surgical 
risks.  However most studies of this method have excluded individuals with α1-
antitrypsin deficiency.  A case series reported the effect of treating 15 
individuals with α1-antitrypsin deficiency with one-way endobronchial valves.  
The recipients had gas trapping (residual volume of 140% or more), airflow 
obstruction (forced expiratory volume in 1 s (FEV1) 15-45% of predicted) and 
severe heterogeneous emphysema.   One individual coughed up valves after 
2 months, 1 developed a pneumothorax and had valve displacement and 
subsequent removal and 1 improved from an FEV1 of 0.62 to 0.84 liters, but 
after 4 months developed repeated and severe pneumonia and the valves 
had to be removed.  The remaining 12 individuals were followed up for at 
least 1 year: FEV1 increased by a mean of 54%, quality of life was much 
improved and 2 individuals were taken off oxygen therapy.  There was no 
significant deterioration in lung function during the 4-year follow-up [72]. 
 
Treatment for liver disease associated with α1-antitrypsin deficiency 
Currently there is no disease-specific therapy for the hepatic manifestations of 
α1-antitrypsin deficiency.  However the detailed understanding of its 
pathobiology has both identified important disease mechanisms to target, and 
also made it an ideal model for the application of novel biomedical 
technologies.  As a result, several novel parallel and complementary 
therapeutic approaches are in trials and in development. 
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(i) Increasing the clearance of inclusions by stimulating autophagy.  
Different groups have assessed a range of chemical chaperones that stabilise 
intermediates on the Z α1-antitrypsin folding pathway [73].  Some were 
effective in cell and animal models of disease [74] but human trials have been 
disappointing [75].  David Perlmutter’s group (Pittsburgh, USA) have taken the 
exciting approach of using an FDA-approved drug, carbamazepine to 
stimulate degradation pathways to clear intracellular polymers of α1-antitrypsin 
[76].  This is now being assessed in a clinical trial (NCT01379469).  
Autophagy may also be enhanced by rapamycin (sirolimus) when given in 
weekly dose pulses, rather than as a daily regimen.  Weekly dosing of 
rapamycin increased the number of autophagic vacuoles and reduced the 
accumulation of intrahepatic polymerised Z α1-antitrypsin. It also reduced 
other markers of hepatocellular injury including cleavage of caspase 12 and 
hepatic fibrosis [77].  Caspase 12 is one of the inflammatory caspases that 
has homology to caspases 4 and 5 in humans. It plays a role in ER stress 
induced apoptosis in the mouse but not in man [78].  Autophagy can be 
induced by viral vectors that overexpress the autophagy regulator 
transcription factor EB (TFEB).  This reduced the accumulation of Z α1-
antitrypsin polymer, apoptosis and fibrosis in the liver of the transgenic mouse 
that expresses Z α1-antitrypsin [79].  These approaches reduce intracellular 
α1-antitrypsin burden and decrease hepatic fibrosis in a mouse model of 
disease. The challenge will be to demonstrate efficacy in man. 
 
(ii) Modifying proteostasis networks. 
An alternative approach is to consider chaperone-mediated folding and 
degradation as part of a robust and cooperative proteostatic network.  
Suberoylanilide hydroxamic acid (SAHA) increases the secretion of Z α1-
antitrypsin from epithelial cell lines to a level of 50% of that observed for wild-
type α1-antitrypsin [80]. It is believed to act in part by inhibition of histone 
deacetylase (HDAC)7.  Such strategies also have the potential to boost 
secretion of less polymerogenic α1-antitrypsin variants to ameliorate lung 
pathology e.g. in SZ compound heterozygotes.  However this approach has 
yet to be assessed in animal models of disease. 
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 (iii) Silencing expression of Z α1-antitrypsin. 
Two pharmaceutical companies (Arrowhead Research Corporation and 
Alnylam Pharmaceuticals Inc.) have developed RNA interference (RNAi)-
based approaches to silence Z α1-antitrypsin production in hepatocytes [81, 
82].  These use small interfering (si)RNA constructs targeted against mRNA 
encoding human α1-antitrypsin and conjugated with hepatocyte targeting 
motifs.  Treatment reduces circulating levels of α1-antitrypsin and both soluble 
and aggregated hepatic α1-antitrypsin protein in transgenic mice expressing Z 
α1-antitrypsin [83].  Moreover administration of the siRNA constructs arrests 
the progression of liver disease in these animals after short-term treatment, 
reverses liver disease after long-term treatment, decreases liver fibrosis and 
prevents liver disease in young animals.  It also leads to marked reduction in 
liver fibrosis.  The administration of RNAi treatment to non-human primates 
led to an approximately 80% reduction in levels of circulating normal α1-
antitrypsin, demonstrating potential for this approach in man. RNAi thus 
represents a promising therapy for α1-antitrypsin deficiency related liver 
disease and is now in a phase I/II clinical trial (NCT02503683).  The study 
started in July 2016 and aims to assess safety, tolerability, pharmacokinetics 
and pharmacodynamics of subcutaneously administered antisense α1-
antitrypsin in healthy adult subjects and individuals with Z α1-antitrypsin 
deficiency liver disease. 
 
(iv) Small molecule approach to block intracellular polymerisation. 
We have used our understanding that Z α1-antitrypsin polymerisation 
underlies the liver accumulation and subsequent plasma deficiency to develop 
novel strategies to attenuate polymerisation and thereby ‘cure’ α1-antitrypsin 
deficiency.  Our early work showed that reactive loop peptides could bind to 
α1-antitrypsin and block polymerisation of purified protein in vitro [2, 84, 85].  
Smaller, refined peptides were developed that had a similar effect with more 
specificity for Z, rather than M, α1-antitrypsin [16, 86-88].  However the 
challenge is to deliver these peptides to cells, let alone to a human liver.  A 
more recent approach has been to use our understanding of the structural 
biology of polymers to develop small molecules to block polymerisation.   The 
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starting point was the identification of a hydrophobic pocket in α1-antitrypsin 
that is bounded by strand 2A and helices D and E [89]; Fig. 4.  The cavity is 
patent in the native protein but is filled as β-sheet A accepts an exogenous 
reactive loop peptide during polymerisation.  The introduction of Thr114Phe 
on strand 2 of β-sheet A filled this cavity, retarded polymer formation in vitro 
and increased the secretion of Z α1-antitrypsin from a Xenopus oocyte 
expression system [46, 90].  This cavity was used as a target for rational 
structure-based drug design to block polymer formation [91].  Virtual ligand 
screening was performed on 1.2 million small molecules and 66 compounds 
were identified as potential binders.  Compounds were identified that 
completely blocked polymerisation in vitro and in cell models of diseas [91].  
This work represented a ‘proof of principle’ rather than a new therapy.  It was 
the basis of a DPAc (Discovery Partnership with Academia) partnership with 
GlaxoSmithKline to develop small molecules that are effective in treating α1-
antitrypsin deficiency (http://www.cam.ac.uk/research/news/new-
collaboration-to-develop-treatments-for-liver-disease/). 
 
(v) Intrabodies to block intracellular polymerisation and increase secretion 
More recently we have used monoclonal antibody technology to identify 
interactors with Z α1-antitrypsin.  This has proved to be powerful technology 
that has allowed us to identify antibodies that specifically detect the polymeric 
[7] and latent [92] conformers of α1-antitrypsin and antibodies that can 
accelerate [93] and block [94] polymer formation.  The 4B12 monoclonal 
antibody blocked α1-antitrypsin polymerisation in vitro at a 1:1 molar ratio, 
causing a small increase of the stoichiometry of inhibition of neutrophil 
elastase [94].  Expression of a single chain-variable-fragment (scFv) intrabody 
of mAb4B12 within the ER reduced the intracellular polymerisation of Z α1-
antitrypsin by 60% and increased the secretion of Z α1-antitrypsin that 
retained inhibitory activity against neutrophil elastase.  The 4B12 monoclonal 
antibody recognises a discontinuous epitope in E32/H43/L306 α1-antitrypsin, 
and acts by altering protein dynamics rather than binding preferentially to the 
native state, analogous to the Z mutation.  This novel approach could reveal 
new target sites for small-molecule intervention that block the transition to 
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aberrant polymers without compromising the inhibitory activity of Z α1-
antitrypsin [94]. 
 
(vi) Stem cell technology to generate models of disease and novel therapies 
for α1-antitrypsin deficiency   
Human induced pluripotent stem cells (hIPSCs) promise great opportunities 
for modelling of human disease as they allow the expression of proteins of 
interest from endogenous promoters.  Dermal fibroblasts have been isolated 
from individuals with α1-antitrypsin deficiency and used to generate patient-
specific hIPSC lines.  Each of the hIPSC lines was differentiated into 
‘hepatocyte-like cells’ using a novel and simple three step differentiation 
protocol in chemically-defined conditions.  The patient-specific hIPSC derived 
hepatocytes show the key pathological features of α1-antitrypsin deficiency: 
protein misfolding, the formation of pathological polymers and the retention of 
polymers in the ER [95, 96].  These cells provide an invaluable resource for 
modelling α1-antitrypsin deficiency and genetic diseases.  We extended this 
work to correct the genetic defect responsible for Z α1-antitrypsin deficiency 
within the hIPSC.  This was targeted using a combination of engineered Zinc 
finger nucleases and a piggyBac donor vector [97].  This efficient gene editing 
technique restored normal structure, function and secretion of α1-antitrypsin in 
subsequently derived liver cells.  These cells secreted both albumin and α1-
antitrypsin when introduced into a mouse model of liver injury.  The challenge 
is to refine the strategy, most likely with CRISPR technology, to obtain cells 
that are more like the fully-differentiated hepatocyte and which are safe to use 
in man.  Nevertheless such an approach may address both the liver and lung 
disease associated with α1-antitrypsin deficiency. 
 
A Clinical Service Perspective 
We believe that patients with α1-antitrypsin deficiency are best cared for in 
collaboration with centres that offer joint respiratory-hepatology expertise.  
Such services need access to appropriate diagnostics (including sequencing 
for the SERPINA1 gene that encodes α1-antitrypsin) and clinical genetics.  We 
have therefore established these within the London Alpha-1 Antitrypsin 
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Deficiency Service.  Here we monitor the lung manifestations with regular 
spirometry, lung volumes and gas transfer supplemented by CT scan where 
this would alter management.  We monitor the liver manifestations using liver 
biochemistry and AFP, transient elastography and liver ultrasound.  We have 
a low threshold of liver biopsy when the above tests are abnormal.  The 
management of lung disease in the UK is as for α1-antitrypsin replete COPD.  
From a liver perspective, patients with α1-antitrypsin deficiency are advised to 
maintain a normal body composition and not drink alcohol to excess.  As 
outlined here, further research is likely to lead to clear-cut benefits for the 
clinical management of α1-antitrypsin deficiency in the relatively near future. 
Translational research capacity is therefore integrated into the service, 
including the opportunity for patients to participate in new therapeutic trials as 
they arise. 
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Figure legends 
 
Figure 1.  (A) Crystal structure of native α1-antitrypsin, solved to atomic 
resolution (1.8 Å, PDB ID 3NE4, [98]) and shown in ribbon representation with 
key features indicated. The reactive loop (red) inserts as a central, 4th strand 
in β-sheet A (i.e. strand 4A) that is shown in blue, during stabilising 
conformational transitions, e.g. to execute antiprotease action or during 
polymerisation.  Beta-sheet B is shown in gold, and β-sheet C in green, with 
strand names indicated.  The arrow indicates the site of the Z (Glu342Lys) 
mutation, within the breach region where initial intramolecular loop insertion 
may occur.  Other pathogenic mutations affecting α1-antitrypsin and other 
members of the serpin superfamily also cluster within the shutter region that 
regulates patency of the reactive loop insertion site.  Reactive loop insertion 
requires expansion of β-sheet A to close the lateral hydrophobic pocket, and 
so this can act as a site for allosteric control of conformational change. (B)  
Three models of α1-antitrypsin polymerisation.  Linkage motifs are indicated 
by boxes, intermolecular β-strand insertion/complementation sites by arrows. 
(i) Single strand (reactive loop) linkage model of polymerisation; (ii) β-hairpin 
(strands 5A+6A) linkage model; (iii) Triple-strand (C-terminal motif: β-strands 
1C, 4B+5B) linkage model. 
 
Figure 2.  Z α1-antitrypsin polymers have a 'beads on a string' appearance.  
Reproduced from [17] with permission. 
 
Figure 3 Biology of α1-antitrypsin (upper panel) and pathobiology of its 
misfolding, polymerisation and deficiency (lower panel) in the liver and the 
lung.  The defined and proposed pathogenic mechanisms fall into 3 general 
categories: 
(I) Toxic gain-of-function consequences of misfolding and polymerisation - 
intracellular 
(II) Loss of physiological function due to lack of native α1-antitrypsin  
(III) Toxic gain-of-function of polymeric α1-antitrypsin – extracellular 
 
Images within diagram used with permission from reference [2]. 
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Figure 4. Allosteric targeting of α1-antitrypsin polymerisation by small 
molecules for drug development.  Left panel: Purple mesh indicates initial 
volume within the lateral cavity for targeting of small molecules to block 
polymerisation [89, 91].  Right panel: Subsequent X-ray crystallographic 
studies further defined a minimal target within the pocket (cyan mesh upper 
panel, transparent volume, lower panel) against which smaller compounds 
could be targeted in silico, lower panel [13]. 
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